<DOC>
	<DOCNO>NCT02334735</DOCNO>
	<brief_summary>Vaccine adjuvant compound used increase specific immune response antigen , minimal toxicity last immune effect . This study investigate use dendritic cell adjuvant NY-ESO-1 Melan-A/MART-1 peptide compare Montanide® study subject melanoma complete clinical remission .</brief_summary>
	<brief_title>A Comparison Matured Dendritic Cells Montanide® Study Subjects With High Risk Melanoma Recurrence</brief_title>
	<detailed_description>This Phase II open label , randomize two-arm study evaluate safety , tolerability , immunogenicity Poly-ICLC mature DCs adjuvant NY-ESO-1 Melan-A/MART-1 peptide ( ARM A ; DC Vaccine ) compare Montanide® ISA-51 VG ( ARM B ; Montanide Vaccine ) , systemic administration Poly-ICLC day 1 2 study subject melanoma complete clinical remission high-risk disease recurrence .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Willing able give write informed consent Histologic diagnosis malignant melanoma , stag IIBIV radiologically confirm complete clinical remission without clinical evidence disease At least 4 week since surgery prior first dose study agent Required value initial laboratory test : Neutrophil count ≥ 1.0 x 10⁹/L Platelet count ≥ 80 x 10⁹/L Hemoglobin ≥ 10.0 g/dL Serum creatinine ≤ 2.0 x mg/dL AST/ALT ≤ 2.0 x upper limit institutional normal Serum bilirubin ≤ 2.0 x upper limit institutional normal No active chronic infection HIV , Hepatitis B , Hepatitis C ECOG performance status ≤ 2 Life expectancy ≥ 6 month Men woman , ≥ 18 year age Serious illness , e.g. , serious infection require antibiotic Previous bone marrow stem cell transplant Study subject know chronic infection HIV , hepatitis B C. Testing perform study subject exhibit clinical sign infection confirm history infection Study subject know autoimmune disease [ e.g . SLE , RA ] significant symptom within past 3 year . Study subject vitiligo exclude Metastatic disease central nervous system Other malignancy within 3 year prior entry study , except treat earlystage melanoma nonmelanoma skin cancer , cervical carcinoma situ , incidental localized prostate cancer treat prostatectomy radiation therapy Prior chemotherapy tumor vaccine therapy Radiation therapy major surgery within 4 week prior first dose study agent Concomitant treatment systemic corticosteroid great physiologic dos . Topical ( propose vaccination site ) inhalational steroid permit Participation clinical trial involve another investigational agent within 4 week prior first dose study agent Pregnancy lactation . Pregnancy test must negative woman reproductive potential baseline must agree use birth control measure study Study subject previously treat one peptide use trial , melanoma protein vaccine , melanoma whole cell vaccine , Montanide eligible Any underlying medical psychiatric condition , opinion investigator make administration study agent hazardous obscure interpretation AEs Lack availability study subject immunological clinical follow assessment Children &lt; 18 year age Allergy shellfish</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>DC Vaccine</keyword>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>